A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia

Clinical Infectious Diseases

Volumn 24, Issue 5, 1997, Pages 854-859

  O'Brien, John G ^a   Dong, Betty J ^b   Coleman, Rebecca L ^b   Gee, Lauren ^b   Balano, Kirsten B ^b  

^a Pace Clinic   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AMINOTRANSFERASE; AMPHOTERICIN B; CREATININE; FUROSEMIDE; GLUCOSE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAMIDINE; POLYSTYRENESULFONATE SODIUM; VANCOMYCIN;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; ETHNIC GROUP; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERKALEMIA; HYPOGLYCEMIA; INTRAVENOUS DRUG ABUSE; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

EID: 0031000844     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.5.854     Document Type: Article

References (24)

1. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention. HIV/AIDS surveillance report: year-end edition. Atlanta: Centers for Disease Control and Prevention, 1993.
2. Montaner JSG, Lawson LM, Levitt N, Belzberg A, Schechter MT, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;113:14-20.
3. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. Ann Intern Med 1988;109:280-7.
4. Wharton JM, Coleman DL, Wofsy CD, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, randomized trial. Ann Intern Med 1986;105:37-44.
5. Sattler FR, Frame P, Davis R, et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS clinical trials group protocol 029/031. J Infect Dis 1994;170:165-72.
6. Allegra CJ, Chabner BA, Tuazon CU, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1987;317:978-85.
7. Sattler FR, Allegra CJ, Verdegem TD, et al. Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia. J Infect Dis 1990;161:91-6.
8. Klein NC, Duncanson FP, Lenox TH, et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS 1992;6:301-5.
9. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495-9.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30: 239-45.
11. Harb GE, Alldredge BK, Coleman R, Jacobson MA. Pharmacoepidemiology of adverse drug reactions in hospitalized patients with human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1993;6: 919-26.
12. Liang K.Y, Zeger SF. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. Lachaal M, Venuto RC. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med 1989;87:260-3.
15. Briceland LL, Bailie GR. Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS. DICP Drug Intell Clin Pharm 1991; 25:1171-4.
16. Comtois R, Pouliot J, Vinet B, Gervais A, Lemieux C. Higher pentamidine levels in AIDS patients with hypoglycemia and azotemia during treatment of Pneumocystis carinii pneumonia. Am Rev Respir Dis 1992; 146:740-4.
17. Wordell CJ, Hauptman SP. Treatment of Pneumocystis carinii pneumonia in patients with AIDS. Clin Pharm 1988;7:514-27.
18. Conte JE Jr. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J Infect Dis 1991;163: 169-75.
19. Stahl-Bayliss CM, Kalman CM, Laskin OL. Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome. Clin Pharmacol Ther 1986;39:271-5.
20. Waskin H, Stehr-Green JK, Helmick CG, Sattler FR. Risk factors for hypoglycemia associated with pentamidine therapy for Pneumocystis pneumonia. JAMA 1988;260:345-7.
21. Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis: determinant roles of renal failure and drug accumulation in a study of 128 patients. Diabetes Care 1995;18: 47-55.
22. Grunfeld C, Kotler DP. Pathophysiology of the AIDS wasting syndrome. AIDS Clin Rev 1992;191-224.
23. Macallan DC, Noble C, Baldwin C, Foskett M, McManus T, Griffin GE. Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. Am J Clin Nutr 1993;58:417-24.
24. Cunningham EE, Brentjens JR, Zielezny MA, Andres GA, Venuto RC. Heroin nephropathy: a clinicopathologic and epidemiologic study. Am J Med 1980;68:47-53.